There are basically two stages to malignant disease irrespective of the primary site of the tumour. The tumour is 'early' if it is still localized and it is then potentially curable by local radical surgery. Once the tumour has disseminated the disease is advanced and local therapy alone cannot cure the patient. It is important, therefore, to differentiate between these two stages before starting treatment. The TNM classification helps one determine the extent of the disease and thus to define the stage ofcancer.
Although the TNM classification is well described in the majority of textbooks, very few mention modern methods of determining distant metastases, even though the prognosis depends on the degree of dissemination. Galasko (1972) examined 138 consecutive patients with mammary carcinoma who were thought to have a locally operable tumour. Each patient had a careful clinical examination, an X-ray of their chest and a radiographic skeletal survey. One patient was found to have hepatomegaly, on biopsy shown to contain tumour cells. One patient had pulmonary metastases shown on her chest X-ray. These were asymptomatic. Four patients had skeletal metastases evident on their skeletal radiographs. Three of these patients had complained of some pain but in the fourth the lesions were completely symptom free. Using these routine procedures, evidence of dissemination was found in 6 (4%) ofthe patients.
Lymph Node Metastases
The commonest site of dissemination of cancer is to the regional lymph nodes and the prognosis is related to the degree of lymph node involvement (Huvos et al. 1971 , Johnstone 1972 . Unfortunately, clinical examination of the lymph nodes is inaccurate and lymphangiography and lymph node scintigraphy have been disappointing.
Skeletal Metastases
The commonest site of distant metastatic involvement is the skeleton, yet conventional methods of detecting skeletal metastases are crude. Galasko (1972) investigated 86 patients with advanced mammary carcinoma and who had skeletal metastases evident on X-ray. Only 65% of this group of patients complained of pain, tenderness was elicited in 16 % and the alkaline phosphatase was raised in 66%. Other biochemical parameters were even less accurate.
X-ray examination is also inaccurate. Edelstyn et al. (1967) found that at least 50% of the bone, in the beam axis of the X-ray, must be destroyed before the lesion is seen radiologically.
During the past few years scintigraphy has been shown to be more accurate and sensitive than conventional methods for the early detection of skeletal metastases. We investigated 50 patients with advanced mammary carcinoma. In 25 patients (50%) metastases were evident on the X-rays which were taken when they first presented to the clinic. Forty-two patients (84 %) had lesions evident on their "IF scintigram which was obtained within a few days of the radiographic skeletal survey. Jaffe (1958) stated that approximately 85 % ofsuch a group ofpatients would have skeletal metastases evident at autopsy. In 36 (72%) of the patients additional lesions, which were not present on X-ray, were seen on the scintigram. These additional lesions have since been confirmed either on subsequent X-rays or at autopsy (Galasko 1972) . Roy et al. (1971) found similar results in prostatic carcinoma.
We also investigated 50 patients with apparently early mammary carcinoma. Each patient had a careful clinical examination, a radiographic skeletal survey and an X-ray of her chest. In each patient the primary tumour was thought to be operable, there was no evidence of dissemination of their disease and the radiographic skeletal survey and chest X-ray were entirely normal. Each patient also had an "8F skeletal scintigram and in 12 (24%) lesions were found on the scintigram. These patients have been followed up for five years (Table 1) . The scintigraphic findings have been confirmed in all the patients with a positive scintigram and 9 (75 %) of these patients have died of cancer during this period. One patient decided to return to Jamaica, when she developed skeletal and pulmonary metastases, and has been lost to follow up. During this same period 10 (26%) of the patients with a negative scintigram have developed evidence of either local Cuschieri (1973) found that the urinary hydroxyproline was persistently elevated in patients who subsequently developed skeletal metastases and suggested that its measurement may be a sensitive index of the presence of occult skeletal metastases.
Metastases at Other Sites The value of hepatic and pulmonary scintigraphy, in the assessment of dissemination of the cancer, has also been investigated (Poulouse et al. 1969 , Castagna et al. 1972 . Although asymptomatic lesions were detected in a number of patients, the results were not as dramatic as those obtained with skeletal scintigraphy, and there is a high false positive and negative rate.
Tumour Localizing Agents
The main drawback to organ scintigraphy is that it only detects metastases in a specific organ. What is obviously needed is a method of detecting cancer at all sites, irrespective of whether it is primary or secondary. Attempts have been made to find tumour localizing agents. The two most successful to date are tagged bleomycin and gallium67. They have a high percentage accuracy for the detection of tumours which are obvious on clinical or radiological examination but the results obtained with the detection of occult lesions have been disappointing (Higasi et al. 1972 ).
Humoral Factor
Another method of detecting carcinoma is to look for a humoral factor which is present in patients with malignant disease. For this factor to be of value it must be tumour specific, present in the serum, decrease with successful treatment of the tumour and increase again should the tumour recur, and it should be readily measurable.
The carcinoembryonic antigen was described by Gold & Freedman (1965) . Unfortunately, it is not tumour specific. It has been found in approximately 73 % of cancers of the colon and rectum, 92 % of cancers of the pancreas, 67 % of cancers of the liver and 60 % of miscellaneous gastrointestinal carcinomata. However, it is also found in 9% of patients with polyps of the colon and rectum, 21 % of patients with inflammatory disease of the colon, 42 % of cirrhotics and 53 % of patients with acute pancreatitis. It is present in 52 % of patients with carcinoma of the breast but also in 4% of patients with benign mammary tumours and 7% of patients with fibroadenosis. It has been found in 72% of patients with carcinoma of the bronchus and in 38% of patients with pulmonary tuberculosis and 25 % of chronic bronchitics. In all these patients the neoplasm was clinically overt (Laurence & Neville 1972 , MacSween et al. 1972 .
Its most important use may be in the detection of recurrence. If present, it should return to normal if the tumour has been completely removed. The earliest evidence of recurrence may be an elevation of the carcinoembryonic antigen.
The a-feto protein is more tumour specific although it is found in a variety of tumours. It is found in 31-78% of hepatic carcinomata, 80% of testicular tumours, 22% of pancreatic carcinomata, 17 % of gastric carcinomata, 7 % of bronchogenic carcinomata and 4.6 % of colonic carcinoma. It is not raised in patients with inflammatory disease (Laurence & Neville 1972) .
Summary
(1) There are basically two stages to malignant disease.
(2) The disease is early if the tumour is still localized and it is then potentially curable by local radical surgery.
(3) Once the carcinoma has disseminated the disease is advanced and local therapy alone cannot cure the patient. (4) It is important to differentiate between these two stages before starting therapy. (5) The skeletal scintigram is the most accurate of the techniques currently available for the early detection of distant dissemination. (6) What is needed is a method of detecting tumour at all sites, whether they are primary or secondary. The results obtained with the methods currently available are somewhat disappointing.
